Will Dendreon Plunge Again?

In this video, health care analysts David Williamson and Max Macaluso discuss Dendreon's upcoming third-quarter earnings. David highlights what investors need to look for in the company's press release -- and more importantly, the conference call. Watch and be prepared for Friday's big news.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 01, 2012, at 5:00 PM, lebronz wrote:

    David,

    How is it that Provenge sales are declining since FDA approval? Here are the quarterly sales revenue numbers since FDA approval of Provenge back in April 2010:

    Q2/10: $2.8M

    Q3/10: $20.2M

    Q4/10: $25M

    2010 Revenue Total: $48M

    Q1/11: $27M

    Q2/11: $48.1M

    Q3/11: $64.3M

    Q4/11: $77M

    2011 Revenue Total: $216M

    Q1/12: $82M

    Q2/12: $80M

    Q3/12: TBD

    Q4/12: TBD

    2012 Revenue Total: On track to do $322M

    Yes, we had a $2M drop from Q1 to Q2 this year, but look at the overall quarterly sales trend since launch.

    If dndn does $80M in the 3rd and 4th quarters, thats $322M total for 2012...., or 3 years of consecutive year over year growth!!!

    Why do you continue to mis-lead readers on Dendreon sales in your videos?

    And, more importantly, why do you leave out current short interest numbers, which have trended upward since November 2011 from 23 million short to almost 47 million short TODAY? Mega wealthy institutional hedgefunds shorting millions of shares each month over the last 12 months is what's been driving the stock price downward, not people selling shares.

    Check the NASDAQ yourself and verify the facts yourself

    http://www.nasdaq.com/symbol/dndn/short-interest

    Please stop spewing FUD around a biotech company that is doing wonderful things for dying pc patient only to get hits on your videos.

    Well, that's not working either really since I'm the only one commenting and telling the truth.

    LEB

  • Report this Comment On November 03, 2012, at 5:40 AM, GDoc77 wrote:

    Maybe, just maybe... they are working for the sell side...?? In this business I hardly trust their advice...GDoc...

Add your comment.

DocumentId: 2089929, ~/Articles/ArticleHandler.aspx, 4/16/2014 6:46:32 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.


Advertisement